CD79B and diffuse large B-cell lymphoma: Overall, more than 65% of alterations were discovered in apoptosis and NF-κB pathway components, including MYC and RHOA. The MYC and RHOA mutations played the leading role in the variants, followed by PIM1, MEF2B, MYD88, and CD79B. For EBV-negative DLBCL patients, KMT2D, CREBBP, PIM1, TNFAIP3, and BCL2 were the most frequently altered genes.